Current studies on XIAP inhibitors for HCC have shown that LCL161 demonstrated synergistic effects with paclitaxel on HCC cells by modulating BCL-2, while Embelin modulated apoptosis and cell cycle by inhibiting XIAP and thus regulating cyclin D1 (22, 23). Here, BCL2 is linked to hepatocellular carcinoma.